Tokyo, Sept. 24 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059169) titled 'Lung Cancer Genomic Screening Project for Individualized Medicine in Asia' on Sept. 23.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center
Condition:
Condition - Lung cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To elucidate the clinicopathological and molecular biological characteristics of lung cancer with genetic abnormalities and altered protein expression.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 16
years-old
=1500/mm3
ii) Hemoglobin : >=8.0 g/dl
iii) Platelet count : >=7.5 x 104/mm3
iv) AST, ALT : <=ULN (upper limit of normal) x 2.5 (x 5 in patients with liver metastasis)
v) Total bilirubin : <=ULN x 1.5
7) Patients without serious complications (e.g., interstitial pneumonitis, poorly controlled diabetes mellitus, cardiac disease, infection, etc.)
8) Patients who are expected to live for at least 3 months from the date of study enrollment
9) Patients who are able to submit samples that can be used for genetic analyses. The samples must be ones collected before the initial drug treatment
10) Patients who wish to enroll in genotype-directed clinical trials if the target gene alterations are identified in this study
11) Patients who have provided written consent to enroll in this study
Key exclusion criteria - none
Target Size - 5000
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2024 Year 01 Month 31 Day
Date of IRB - 2024 Year 06 Month 20 Day
Anticipated trial start date - 2024 Year 06 Month 27 Day
Last follow-up date - 2044 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067678
Disclaimer: Curated by HT Syndication.
